Protagonist Therapeutics, Inc. PTGX 深 滬
已收盤 08-07 16:00:00 美东时间
145.87
-0.310
-0.21%
華盛通- 最 高147.32
- 今 開146.18
- 成交量 32.11万股
- 最 低 144.44
- 昨 收 146.18
- 總市值 93.81亿
- 52周最高 148.00
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 54.50
- 委 比 5.39%
- 總股本 6431.14万
- 歷史最高 148.00
- 量 比 0.55
- 振 幅 1.97%
- 歷史最低 4.47
- 每 手 1
- 風險率 21.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $151 to $153.
08-06 22:48
财报速睇 | Protagonist Therapeutics, Inc. 2026财年Q2营收2.13亿美元，同比增长3749.2%；归母净利润1.63亿美元，扭亏为盈
华盛资讯8月6日讯，Protagonist Therapeutics, Inc.公布2026财年Q2业绩，公司Q2营收2.13亿美元，同比增长3749.2%，归母净利润1.63亿美元，扭亏为盈。
08-06 08:47
Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $1.66 by 37.95 percent. This is a 516.36 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $213.4...
08-06 06:07
财报速睇 | Protagonist Therapeutics, Inc. 2026财年Q2营收2.13亿美元，同比增长3749.2%；归母净利润1.63亿美元，扭亏为盈
华盛资讯8月6日讯，Protagonist Therapeutics, Inc.公布2026财年Q2业绩，公司Q2营收2.13亿美元，同比增长3749.2%，归母净利润1.63亿美元，扭亏为盈。
08-06 04:48
美股大行评级 | 美银上调AMD目标价从550美元升至620美元；IBM暴跌25%！大摩上调目标价升至293美元，汇丰下调评级至"卖出"目标价降至191美元
今日重点评级关注：Keybanc：维持迈威尔科技"超配"评级，目标价从385美元升至400美元；丰业银行：维持科尔黛伦矿业"跑赢大市"评级，目标价从27.5美元升至28.5美元
07-15 10:22
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $119 to $151.
07-14 19:39
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $145
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $121 to $145.
07-07 19:37
This $300 Million Biotech May Be Deeply Mispriced: Analyst
Cantor Fitzgerald initiated coverage of Silence Therapeutics Plc (NASDAQ:SLN) with an Overweight rating, arguing that the biotech’s lead candidate divesiran could emerge as a major challenger in the polycythemia vera market, with upcoming Phase 2 data expected in August serving as a potentially tran...
06-25 02:22
